This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, A. V. Articles by Hadsell, D. L. Search for Related Content PubMed PubMed Citation Articles by Lee, A. V. Articles by Hadsell, D. L.

New Mechanisms of Signal Transduction Inhibitor Action

Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation¹

Departments of Medicine and Molecular and Cellular Biology, Breast Center [A. V. L., R. S., X. C., S. O.] and Department of Pediatrics [D. L. H.], Baylor College of Medicine, Houston, Texas 77030; University of Minnesota Cancer Center, Minneapolis, Minnesota 55455 [D. S., D. Y.]; and School of Biological Sciences, University of Manchester, Manchester, United Kingdom [A. P. G., C. H. S.]

The explosion of signal transduction research over the last 10 years has provided a unique insight into the complexity of these intricate pathways. Whereas intermediates of multiple signaling pathways have been identified, understanding their function and, in particular, the interactions between them has become a daunting task. The increasing evidence that many of these pathways can cross-talk with each other via signal transactivation inevitably raises the question of how cells determine specificity in signaling. Despite the mind-numbing complexity of these pathways, progress has been made in developing highly specific and potent signal transduction inhibitors (STIs). STIs show promise in the treatment of cancer in preclinical studies and are currently in a number of clinical trials. Whereas many of these agents were "rationally designed," we barely understand their mechanisms of action. This review will highlight how recent studies using these STIs have elucidated novel mechanisms of STI action that may be used in the development of new therapeutic strategies for the treatment of cancer.

This article has been cited by other articles:

				J. M. Tikkanen, M. Hollmen, A. I. Nykanen, J. Wood, P. K. Koskinen, and K. B. Lemstrom Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease Am. J. Respir. Crit. Care Med., November 15, 2006; 174(10): 1145 - 1152. [Abstract] [Full Text] [PDF]